Alaunos Therapeutics (NASDAQ:TCRT) Announces Earnings Results, Beats Expectations By $1.74 EPS

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) released its earnings results on Monday. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.05) by $1.74, FiscalAI reports.

Alaunos Therapeutics Price Performance

NASDAQ TCRT traded down $0.03 during trading on Monday, hitting $1.60. 61,077 shares of the company’s stock traded hands, compared to its average volume of 2,209,315. The stock has a fifty day moving average of $1.64 and a two-hundred day moving average of $2.28. Alaunos Therapeutics has a 12-month low of $0.72 and a 12-month high of $4.50. The firm has a market cap of $5.30 million, a P/E ratio of -0.84 and a beta of -1.02.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research report on Friday. TD Cowen started coverage on shares of Alaunos Therapeutics in a report on Friday. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Alaunos Therapeutics has a consensus rating of “Hold”.

Read Our Latest Stock Report on Alaunos Therapeutics

About Alaunos Therapeutics

(Get Free Report)

Alaunos Therapeutics was a biotechnology company focused on developing engineered T-cell therapies for cancer. Its research centered on T-cell receptor (TCR) therapies designed to help a patient’s immune cells recognize and attack tumors. The company’s main program investigated genetically modified T cells targeting cancer-associated mutations, including mutations in the KRAS gene, in patients with solid tumors. Its approach used a library of TCRs intended to recognize different tumor mutations.

Further Reading

Earnings History for Alaunos Therapeutics (NASDAQ:TCRT)

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.